spacer
home > epc > spring 2009 >
PUBLICATIONS
European Pharmaceutical Contractor


Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer
News and Press Releases

A new market reference added to SafenSound, our passive safety device platform

SafenSound is on the market in Europe with a newly registered injectable medication. The commercial launch of HULIO (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018. Hulio, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira.
More info >>

White Papers

The BioPharmaSpec Approach: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement